(5 Total References)
Cancer Genetics Introduces Novel CML FISH Assay
Dr. Nallasivam Palanisamy, Ph.D., Director of Genomic Research and Services reported (Poster 622): "Using our novel probe, we studied 70 unselected CML specimens for which t(9;22)(q34.1;q11.2) translocation status was confirmed by G-band karyotype analysis.
continued, "Using our new probe, we identified deletions on the Ph chromosome.
Stretton Scientific UK - FISH Probes
The Probe Diagnostics Group, under the guidance of Dr. RSK Chaganti, Chairman of Cancer Genetics, Inc., and the direction of Dr. Nallasivam Palanisamy, Director of Genomic Research Services, recently launched new FISH probes utilising the innovative Signal Segregation Approach technology.
Dr. Nallasivam Palanisamy, Cancer Genetics Inc.
Detection in metaphase spreads (upper panels) and interphase nuclei (lower panels) of the Bcr-Abl proto-oncogene fusion (yellow signals) as a result of the t (9;22) translocation between chromosomes 9 (9q34, red) and 22 (22q11, green) in patients suffering from Chronic Myeloid Leukaemia (CML), using dGreen- and Rhodamine-ULS labeled BAC DNA probes. (BAC DNA provided by Dr. Nallasivam Palanisamy
, Cancer Genetics, Inc.).
CGI Launches Revolutionary Weapon for the War on Cancer
Nallasivam Palanisamy, Ph.D., Director of Genomic Research and Services reports: "Of the 69 cases previously analyzed [utilizing the CGI two color two fusion signal segregation approach] 60 were known to have the standard t(9;22)(q34.1;q11.2) translocation , and nine were identified with variant translocations.Using the F-FISH assay we have found that of the 60 cases with t(9;22)(q34.1;q11.2), 20% were observed to have deletions on either the der(9) or der(22) and of the 9 cases with variant translocations 44% were noted to have deletions on either the der(9) or der(22)."Deletions on the der(9) chromosome are particularly important as they have been shown to be associated with the resistance to treatment and possibly contribute to poor clinical outcome (Sinclair et al., 2000).Such losses due to submicroscopic deletions are not detectable by conventional G-band analysis. Dr. Palanisamy
continued, "There are a multitude of advantages to the F-FISH BCR/ABL Probe.
Cancer Genetics Awarded Phase II SBIR to Develop Novel Lymphoma Proves
According to Dr. Nallasivam Palanisamy, Ph.D., Principal Investigator and Director of Genomic Research and Services, "Preliminary results show that our probes can be used to both diagnose new non-Hodgkin's lymphoma cases and monitor patients for minimal residual disease following chemo/monoclonal antibody therapy or bone marrow transplantation".
"Compared to conventional probes that identify only one derivative chromosome with a single fusion signal, our dual color, dual fusion probes detect very small numbers of tumor cells present in a population of normal cells, and do not generate false positive signals", Dr. Palanisamy